What's in Jiangsu Simcere Pharmaceutical Co., Ltd.'s pipeline?

Jiangsu Simcere Pharmaceutical Co., Ltd. has 38 drugs in our index: 1 marketed, 0 filed, 10 in Phase 3, 4 in Phase 2, 23 in Phase 1.

Which companies overlap with Jiangsu Simcere Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Institut Bergonié, AstraZeneca, Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jiangsu-simcere-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Jiangsu Simcere Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Jiangsu Simcere Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 10 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 10 Phase 3 4 Phase 2 23 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Levamlodipine besylate	Levamlodipine besylate	marketed	Dihydropyridine calcium channel blocker	L-type voltage-gated calcium channel	Cardiovascular
Bendamustine hydrochloride injection	Bendamustine hydrochloride injection	phase 3	Alkylating agent	DNA	Oncology
ENDOSTAR，cisplatin	ENDOSTAR，cisplatin	phase 3	Angiogenesis inhibitor	Endothelial cells; inhibits VEGF-mediated angiogenesis	Oncology
Endostar continuous intravenous infusion	Endostar continuous intravenous infusion	phase 3	Angiogenesis inhibitor	VEGF signaling pathway; endothelial cells	Oncology
Endostar routine intravenous infusion	Endostar routine intravenous infusion	phase 3	Angiogenesis inhibitor	VEGF signaling pathway; endothelial cells	Oncology
Compound Edaravone Injection	Compound Edaravone Injection	phase 3	Free radical scavenger / Antioxidant	Hydroxyl radicals and reactive oxygen species	Neurology
SIM0270	SIM0270	phase 3
Trilaciclib, carboplatin, etoposide，or Topotecan	Trilaciclib, carboplatin, etoposide，or Topotecan	phase 3	CDK4/6 inhibitor	CDK4/6	Oncology
Suvemcitug injection, trifluridine/tipiracil tablets	Suvemcitug injection, trifluridine/tipiracil tablets	phase 3	Nucleoside analog; antimetabolite	Thymidylate synthase; DNA	Oncology
placebo, carboplatin, etoposide，or Topotecan	placebo, carboplatin, etoposide，or Topotecan	phase 3	platinum-based chemotherapy	DNA	Oncology
Placebo , cisplatin	Placebo , cisplatin	phase 3	Platinum-based chemotherapy agent	DNA	Oncology

Therapeutic area mix

Oncology · 10
Cardiovascular · 1
Neurology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 3 shared drug classes
Sun Yat-sen University · 3 shared drug classes
Institut Bergonié · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Akeso · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Jiangsu Simcere Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Jiangsu Simcere Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-simcere-pharmaceutical-co-ltd. Accessed 2026-05-16.